CN1599622A - 用钙调蛋白激酶ⅱ抑制剂治疗结构性心脏病中的心肌功能障碍 - Google Patents

用钙调蛋白激酶ⅱ抑制剂治疗结构性心脏病中的心肌功能障碍 Download PDF

Info

Publication number
CN1599622A
CN1599622A CNA028241010A CN02824101A CN1599622A CN 1599622 A CN1599622 A CN 1599622A CN A028241010 A CNA028241010 A CN A028241010A CN 02824101 A CN02824101 A CN 02824101A CN 1599622 A CN1599622 A CN 1599622A
Authority
CN
China
Prior art keywords
peptide
inhibitor
seq
camkii
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028241010A
Other languages
English (en)
Chinese (zh)
Inventor
M·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN1599622A publication Critical patent/CN1599622A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
CNA028241010A 2001-10-01 2002-10-01 用钙调蛋白激酶ⅱ抑制剂治疗结构性心脏病中的心肌功能障碍 Pending CN1599622A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32657601P 2001-10-01 2001-10-01
US60/326,576 2001-10-01
US32801001P 2001-10-08 2001-10-08
US60/328,010 2001-10-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN 200610004452 Division CN1840186A (zh) 2001-10-01 2002-10-01 用钙调蛋白激酶ii抑制剂治疗结构性心脏病中的心肌功能障碍
CNA2007101469755A Division CN101130069A (zh) 2001-10-01 2002-10-01 用钙调蛋白激酶ii抑制剂治疗结构性心脏病中的心肌功能障碍

Publications (1)

Publication Number Publication Date
CN1599622A true CN1599622A (zh) 2005-03-23

Family

ID=26985461

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028241010A Pending CN1599622A (zh) 2001-10-01 2002-10-01 用钙调蛋白激酶ⅱ抑制剂治疗结构性心脏病中的心肌功能障碍

Country Status (14)

Country Link
US (2) US7320959B2 (https=)
EP (1) EP1439849A4 (https=)
JP (1) JP2005504829A (https=)
KR (1) KR20040045041A (https=)
CN (1) CN1599622A (https=)
AU (1) AU2002341938B2 (https=)
BR (1) BR0213043A (https=)
CA (1) CA2462443A1 (https=)
IL (1) IL161231A0 (https=)
MX (1) MXPA04003040A (https=)
NO (1) NO20041331L (https=)
NZ (1) NZ532327A (https=)
PL (1) PL369104A1 (https=)
WO (1) WO2003029428A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972447A (zh) * 2021-03-02 2021-06-18 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1815867A4 (en) * 2004-11-02 2010-06-09 Dainippon Sumitomo Pharma Co COMBINATION PREPARATION FOR THE TREATMENT OF AUTOIMMUNE DISEASE
JP5415520B2 (ja) * 2008-04-09 2014-02-12 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最大酸素消費量低下の予測のためのプロ−エンドセリン−１
US8841423B2 (en) * 2008-04-28 2014-09-23 University Of Iowa Research Foundation Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
US20090275514A1 (en) * 2008-05-01 2009-11-05 Anderson Mark E Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation
US20120134971A1 (en) * 2009-05-22 2012-05-31 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Engineered biological pacemakers
US8440656B2 (en) * 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
EP2485749A4 (en) * 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
AU2014225889B2 (en) 2013-03-06 2018-12-06 The Johns Hopkins University CaMKII inhibitors and uses thereof
DE102014201651A1 (de) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen
WO2016037106A1 (en) 2014-09-05 2016-03-10 Allosteros Therapeutics, Inc CaMKII INHIBITORS AND USES THEREOF
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (https=) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JP2001509808A (ja) * 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
JP2963986B2 (ja) * 1997-11-19 1999-10-18 工業技術院長 カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972447A (zh) * 2021-03-02 2021-06-18 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Also Published As

Publication number Publication date
US7632815B2 (en) 2009-12-15
AU2002341938B2 (en) 2007-08-30
JP2005504829A (ja) 2005-02-17
WO2003029428A3 (en) 2003-10-30
IL161231A0 (en) 2004-09-27
EP1439849A2 (en) 2004-07-28
WO2003029428A8 (en) 2004-04-22
US20090011989A1 (en) 2009-01-08
NO20041331D0 (no) 2004-03-31
KR20040045041A (ko) 2004-05-31
US7320959B2 (en) 2008-01-22
NO20041331L (no) 2004-05-28
PL369104A1 (en) 2005-04-18
EP1439849A4 (en) 2005-09-28
NZ532327A (en) 2005-10-28
US20040266675A1 (en) 2004-12-30
BR0213043A (pt) 2004-10-05
MXPA04003040A (es) 2004-07-15
CA2462443A1 (en) 2003-04-10
WO2003029428A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
US7632815B2 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
AU2002337811A1 (en) Adjustable child support structure with accessories
EP1450650A2 (en) Adjustable child support structure with accessories
CN114159436A (zh) 治疗在gla基因中具有g9331a突变的患者的法布里病的方法
AU2002341938A1 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
CN118112249A (zh) 法伯病标志物及其用途
CN1925872A (zh) 紫外线诱导的程序性细胞死亡的抑制方法
AU2005274377B2 (en) Method of screening for a carnitine transporter agonist or antagonist and its uses
CN1840186A (zh) 用钙调蛋白激酶ii抑制剂治疗结构性心脏病中的心肌功能障碍
CN1160119C (zh) Tob基因在哺乳动物中枢神经系统的功能及其应用
CA2560011A1 (en) Cospeptin, cosmedin and their uses
CN1438320A (zh) 利用人cyld基因对肿瘤进行诊断、治疗及药物开发的方法
CN1269416A (zh) 一种新的人爱滋病毒周转蛋白异构体蛋白及其编码序列
AU2007237240A1 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
CN1286305A (zh) 一种新的人膜转移蛋白及其编码序列
NZ541833A (en) Use of calmodulin kinase II inhibitors, mainly SEQ ID NO:4, to treat myocardial dysfunction in structural heart disease
CN1251653A (zh) 校正异常基因产物功能的物质
CN1390852A (zh) 人类心房颤动致病基因和编码蛋白及其用途
CN1268568A (zh) 一种新的人线粒体溶质载体蛋白及其编码序列
HK40001720A (en) Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
CN1343688A (zh) 人nip2相关蛋白和编码序列及其用途
CN1976949A (zh) 离子通道
CN1661072A (zh) 精氨酸升压素受体1a基因与原发性高血压的相关性
CN1272541A (zh) 一种人高尔基体外侧网络蛋白异构体及其编码序列
CN1267733A (zh) 一种人葡萄糖醛酸转移酶蛋白及其编码序列

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned